The News Review:

- Intensive summer program helps physicians build clinical research …
- Imaging Diagnostic Systems Achieves Technical Breakthrough with …
- A Conversation With… Dr. Jorge Gomez
- PennyPerformers.com: “Penny Stocks that Perform” picks are: AEMD …
- Kurt Mussina and Jim Calvin join Trio Clinical Research Management …
- Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 …

Intensive summer program helps physicians build clinical research …
EurekAlert (press release)
A report on the PCE a joint program of Brigham and Women’s Hospital (BWH) and Harvard School of Public Health (HSPH) with strong input from the Massachusetts General Hospital (MGH) from a team of investigators at the three institutions appears in the April issue of Academic Medicine along with several other articles addressing the NIH vision for clinical and translational research. “ur survey found that graduates of the Program in Clinical Effectiveness have been able to successfully obtain grant funding publish gain promotions negotiate protected research time and rise to leadership roles in public health academic medicine and the private sector” says Mary Ellen Goldhamer MD MPH an MGH physician and PCE graduate who led the study. “As far as we know the PCE is the original and largest program focusing on clinical research training for physicians and is distinctive in providing research training with a particular emphasis on clinical trials clinical epidemiology and health services research concurrent with clinical training. The authors note that the number of physician investigators is dropping nationally due to factors such as heavy educational debt the lengthy training required and the challenges of securing grant funding along with time to conduct research. But at the same time research focused on translating basic scientific discoveries into clinical treatments is more important than ever. “The scientific knowledge gained through unraveling the genome and deciphering cellular mechanisms in great detail has not led to commensurate improvement in disease prevention and treatment” says study co-author Daniel E. Singer MD associate director of the PCE and director of the General Medicine Fellowship at MGH.

Imaging Diagnostic Systems Achieves Technical Breakthrough with …
FXBusiness
“The new algorithm has improved the visualization and distinction of several known patterns of angiogenesis from normal patterns of breast perfusion making it easier for the radiologist to detect cancer. f even greater importance; breasts which are too dense to be penetrated by X-ray mammography are quite translucent to the laser beam. The CTLM system therefore has much greater sensitivity than mammography in the dense breast and can reveal between two and three times the number” stated Dr. About Imaging Diagnostic Systems Inc. Imaging Diagnostic Systems Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer.

A Conversation With… Dr. Jorge Gomez
National Cancer Institute – NCI Cancer Bulletin
The majority of the investment NCI has made in the region in past years has been in the form of training grants through Fogarty or through other types of grants and subcontracts so this is a new approach for our collaboration in Latin America. It’s also the first time that we’re collaborating through formal agreements with the ministries of health in Latin America. These government agencies are assembling clinical research networks in their own countries which will basically create a United States–Latin American cancer research network. The health ministries are providing some matching funds for this project so NCI is not doing it alone. We’re also collaborating with their research institutions which work closely with their government agencies. Who attended the workshop and what was accomplished?There were delegations from Argentina Brazil Chile Mexico and Uruguay representatives from different NCI divisions centers and programs and prominent U.
Related from Inkfeenz: Gomez Challenges Burns In Glasgow

PennyPerformers.com: “Penny Stocks that Perform” picks are: AEMD …
Trading Markets (press release)
Xuejun Chen Sinobiopharma’s vice president of sales was also in attendance and expressed Sinobiopharma’s thanks to the participating experts for their commitment to research on Kutai. Sinobiopharma has established a highly specialized professional team of clinical trial monitors as part of the project to keep close surveillance on the patients. The manager of Sinobiopharma’s Clinical Research Department Mr. Lei Wang reported on the Phase IV project clinical monitoring outcomes. The experts’ consensus was that the Phase IV study established Kutai as safe and effective for room temperature storage. The year-long clinical research project showed no significant differences between Kutai and imported Cisatracurium besylate and no significant differences for Kutai safety and effectiveness when stored at either room temperature or a lower temperature. All the participating parties followed the study design and promote inter-communication to ensure compliance with Good Clinical Practice (GCP).

Kurt Mussina and Jim Calvin join Trio Clinical Research Management …
PharmaLive.com (press release)
March 23 2009 – Trio Clinical Research a leading clinical research services company supporting the pharmaceutical biotechnology and medical device industry announced today the appointments of Kurt Mussina as Senior Vice President of Business Development and Jim Calvin as Senior Vice President of Clinical Services. Mussina has over 20 years of international biopharmaceutical business experience and a proven track record in building global sales and marketing organizations in the CR industry. His executive experience spans operating and technical functions as well as managing international sales teams responsible for annually delivering hundreds of millions of dollars in profitable contracts. Prior to joining Trio Clinical Research he served as Vice President Client Services at Aptuit; Vice President Global Clinical Business Development at Inveresk and Director of Sales and Marketing at AAI.

Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 …
FXBusiness
Eastern Time to discuss the results from this Phase IIa clinical trial. Robert Blum Cytokinetics’ President and Chief Executive fficer will be joined by Andrew Wolff MD FACC Cytokinetics’ Senior Vice President of Clinical Research and Development and Chief Medical fficer Fady Malik MD Cytokinetics’ Vice President of Muscle Biology and Cardiovascular Therapeutics and John R. Teerlink MD FACC FAHA FESC Professor of Medicine at the University of California San Francisco and the Director of Heart Failure at the San Francisco Veterans Affairs Medical Center in a discussion of the data. Blum will moderate the session.